Oops, you're using an old version of your browser so some of the features on this page may not be displaying properly.

MINIMAL Requirements: Google Chrome 24+Mozilla Firefox 20+Internet Explorer 11Opera 15–18Apple Safari 7SeaMonkey 2.15-2.23

Poster Display session 3

4577 - Pan-Cancer Genomic Landscape of the Cyclin D1/FGF3,4,19 (11q13) Amplicon Including Associations with HPV Status, and ESR1 and AR Alterations

Date

30 Sep 2019

Session

Poster Display session 3

Topics

Translational Research

Tumour Site

Presenters

Jennifer Johnson

Citation

Annals of Oncology (2019) 30 (suppl_5): v25-v54. 10.1093/annonc/mdz239

Authors

J.M. Johnson1, J. Lee2, R. Madison2, A.B. Schrock3, V.A. Miller2, B.M. Alexander2, J.S. Ross4, J. Chung2, S.M. Ali2

Author affiliations

  • 1 Medical Oncology, Thomas Jefferson University, 19107 - Philadelphia/US
  • 2 Clinical Development, Foundation Medicine, 02141 - Cambridge/US
  • 3 Clinical Development, Foundation Medicine, MA 02141 - Cambridge/US
  • 4 Pathology, Foundation Medicine, 02141 - Cambridge/US

Resources

Login to get immediate access to this content.

If you do not have an ESMO account, please create one for free.

Abstract 4577

Background

The amplicon of CCND1, FGF3, FGF4, and FGF19 on chromosome 11q13 encodes cyclinD1, regulator of the CDK4/6 cell cycle kinase and FGF ligands for FGFR kinases, which are targets for drug development. We sought to characterize the pan-cancer genomic landscape of this amplicon.

Methods

Tumor samples from 255,117 patients with clinically advanced cancers underwent comprehensive genomic profiling (CGP) with an adaptor-ligation/hybrid capture-based assay of coding DNA of up to 395 cancer-related genes and select introns of 28 genes that are frequently involved in genomic rearrangements to detect base substitutions, insertions and deletions, copy number alterations, and rearrangements.

Results

4% (10,202/255,117) of all cases harbored the 11q13 amplicon (+). The median copy number was 12 (range 6-176). Of the 10 cancers where 11q13+ was most frequent, five were squamous cell carcinomas (SCC) including esophagus SCC (ESCC) (47.3% 11q13+) as the most enriched, head and neck SCC (HNSCC) (17.0%), as well as lung SCC (LSCC) (10.8%). Given ESCC and LSCC are overwhelmingly HPV-, we assessed 11q13 occurrence by HPV status in HNSCC. 3.4% of the 11q13+ HNSCC cases were HPV+, compared to 36.8% of the 11q13- HNSCC samples (p = 9.4e-52). 2 (20%) of the 10 cancers most frequently 11q13+ were the classically ER+ breast invasive lobular carcinoma (17.7%) and breast carcinoma NOS (16.6%). In 441 ER+ breast cancers, 286 (19.8%) were 11q13+. Of these ER+/11q13+ cases, 19.2% also featured ESR1. In contrast, only 14.3% of the ER+/11q13- cases also had ESR1 mutations (p = 0.05). Similarly, in 7103 cases of predominantly castrate resistant prostate cancers, 210 (3.0%) featured 11q13+. 38.6% of the 11q13+ prostate cancer cases also harbored mutations in AR while only 19.9% of the 11q13- cases harbored AR mutations (p = 6.2e-11).

Conclusions

SCCs are enriched for 11q13+ with preliminary evidence for linking them to HPV- status. The co-occurrence of 11q13+ with both ESR1 and AR mutations suggests a co-operative role in acquired resistance to hormonal therapy, but not to TKIs. Further investigation will be 11q13+ in the development of SCC and acquired resistance to hormonal therapies appears warranted.

Clinical trial identification

Editorial acknowledgement

Legal entity responsible for the study

Foundation Medicine.

Funding

Foundation Medicine.

Disclosure

J.Johnson: Consultant: Foundation Medicine Consultant: Rakuten-Aspyrian. J. Lee: Full / Part-time employment: Foundation Medicine; Shareholder / Stockholder / Stock options: Roche. R. Madison: Full / Part-time employment: Foundation Medicine; Shareholder / Stockholder / Stock options: Roche. A.B. Schrock: Shareholder / Stockholder / Stock options, Full / Part-time employment: Foundation Medicine; Shareholder / Stockholder / Stock options: Roche. V.A. Miller: Shareholder / Stockholder / Stock options, Full / Part-time employment: Foundation Medicine; Advisory / Consultancy: Revolution Medicines. B.M. Alexander: Leadership role, Full / Part-time employment: Foundation Medicine; Advisory / Consultancy: AbbVie; Advisory / Consultancy: Schlesinger Associates; Advisory / Consultancy: Bristol-Myers Squibb; Advisory / Consultancy: Precision Health Economics; Research grant / Funding (self): Puma; Research grant / Funding (self): Celgene; Research grant / Funding (self): Eli Lilly. J.S. Ross: Leadership role, Shareholder / Stockholder / Stock options, Full / Part-time employment: Foundation Medicine; Shareholder / Stockholder / Stock options: Roche; Officer / Board of Directors: Celsius Therapeutics. J. Chung: Full / Part-time employment: Foundation Medicine; Shareholder / Stockholder / Stock options: Roche. S.M. Ali: Shareholder / Stockholder / Stock options, Full / Part-time employment: Foundation Medicine; Shareholder / Stockholder / Stock options: Roche; Advisory / Consultancy, Scientific Advisory Board: Incysus Therapeutics; Advisory / Consultancy: Revolution Medicines.

This site uses cookies. Some of these cookies are essential, while others help us improve your experience by providing insights into how the site is being used.

For more detailed information on the cookies we use, please check our Privacy Policy.

Customise settings
  • Necessary cookies enable core functionality. The website cannot function properly without these cookies, and you can only disable them by changing your browser preferences.